Dujduan Waraho-Zhmayev

Dr. Dujduan Waraho-Zhmayev

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Molecular Biotechnology
Verified
Journal Article
Open access
PDF file
TTTermsak Tantiwiwat
Termsak Tantiwiwat
ATApisitt Thaiprayoon
Apisitt Thaiprayoon
ASAke-Kavitch Siriatcharanon
Ake-Kavitch Siriatcharanon
CTChakrit Tachaapaikoon
Chakrit Tachaapaikoon
NPNongluk Plongthongkum
Nongluk Plongthongkum
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
The ongoing COVID-19 pandemic has resulted from widespread infection by the SARS-CoV-2 virus. As new variants of concern continue to emerge, understanding the correlation between the level of neutralizing antibodies (NAb) and clinical protection from SAR-CoV-2 infection could be critical in planning the next steps in COVID-19 vaccine programs. This study explored the potential usefulness of E. coli as an alternative expression system that can be used to produce a SARS-CoV-2 receptor-binding domain (RBD) for the development of an affordable and flexible NAb detection assay. We expressed the RBD of Beta, Delta, and Omicron variants in the E. coli BL21(DE3) strain and purified them from whole bacterial cells using His-tag-mediated affinity chromatography and urea-assisted refolding. Next, we conducted a head-to-head comparison of the binding activity of our E. coli-produced RBD (E-RBD) with commercial HEK293-produced RBD (H-RBD). The results of a direct binding assay revealed E-RBD and H-RBD binding with ACE2-hFc in similar signal strengths. Furthermore, in the NAb detection assay, % inhibition obtained from both E-RBD and H-RBD demonstrated comparable results in all the investigated assays, suggesting that non-glycosylated RBD produced from E. coli may offer a cost-effective alternative to the use of more expensive glycosylated RBD produced from human cells in the development of such an assay.

28 January 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ATApisitt Thaiprayoon
Apisitt Thaiprayoon
YCYodpong Chantarasorn
Yodpong Chantarasorn
WOWorrapoj Oonanant
Worrapoj Oonanant
AKAnongnard Kasorn
Anongnard Kasorn
PLPhoomintara Longsompurana
Phoomintara Longsompurana
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
Nanobodies (Nbs) hold great potential to replace conventional antibodies in various biomedical applications. However, conventional methods for their discovery can be time-consuming and expensive. We have developed a reliable protein selection strategy that combines magnetic activated cell sorting (MACS)-based screening of yeast surface display (YSD) libraries and functional ligand-binding identification by Tat-based recognition of associating proteins (FLI-TRAP) to isolate antigen-specific Nbs from synthetic libraries. This combined process enabled isolation of three unique Nb clones (NbT15, NbT21, and NbT22) that all bound specifically to a target antigen, namely proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as a gain-of-function PCSK9 mutant (D374Y). All three clones bound to PCSK9 and blocked the interaction between the low-density lipoprotein receptor (LDLR) and either wild-type PCSK9 or the D374Y mutant. Overall, our combined protein selection method enables rapid and straightforward identification of potent antigen-specific Nbs in a manner that can be executed in a basic laboratory setting without the need for specialized equipment. We anticipate that our strategy will be a valuable addition to the protein engineering toolkit, allowing development of Nbs or virtually any other synthetic binding protein for a wide range of applications.

15 November 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
KIKwanpet Intasurat
Kwanpet Intasurat
NSNonth Submunkongtawee
Nonth Submunkongtawee
PLPhoomintara Longsompurana
Phoomintara Longsompurana
ATApisitt Thaiprayoon
Apisitt Thaiprayoon
WKWarisara Kasemsukwimol
Warisara Kasemsukwimol
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
The urgent need for an effective COVID-19 therapy has propelled the exploration of innovative strategies to combat the fast-mutating SARS-CoV-2 virus. This study attempted to develop nanobodies (Nbs) against the SARS-CoV-2 Omicron variants by redirecting the 1.29 neutralizing Nb, a receptor-binding domain (RBD)-specific Nb that can protect against various SARS-CoV-2 variants other than Omicron, to target SARS-CoV-2 Omicron subvariant BA.5, the variant used for the development of the bivalent vaccine. Error-prone libraries of the 1.29 Nb were constructed. Following two rounds of selection using the functional ligand-binding identification by Tat-based recognition of associating proteins (FLI-TRAP) technique, we rapidly identified two Nbs, namely, C11 and K9, that could target the RBD of the Omicron subvariant BA.5, XBB.1.5, and XBB.1.16 subvariants. Molecular docking provided insights into how these Nbs interact with the RBD of the BA.5 and JN.1 variants. The application of directed evolution via utilization of error-prone PCR and the synthetic E. coli applied in the FLI-TRAP selection method may be a powerful tool for facilitating simple, fast and economical selection to redirect existing antibodies and to generate antibody fragments to target proteins susceptible to autonomous mutation, not only for viral infection but also other diseases, such as cancer.

30 August 2018 in IOP Conference Series: Earth and Environmental Science
Verified
Conference Paper
Open access
PDF file
PCP Charoenpun
P Charoenpun
JLJ Leelawattanachai
J Leelawattanachai
AMA Meechai
A Meechai
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
Monoclonal antibody (mAb) is a very useful tool in not only medical field but also in research field. However, the current cost of its production is very high as most mAbs are produced in mammalian cell system. Escherichia coli is a good alternative but has many bottlenecks. Recently, it was demonstrated that biological active full-length Immunoglobulin G (IgG) could be produced in the reductive cytoplasm of an engineered E. coli strain called SHuffle. In this study, we investigated the effect of temperature and induction level on the production of full-length humanized anti-Her2 and chimeric anti-VEGF IgGs expressed as cyclonal. The solubility as well as the assembly of the IgG molecules was examined by western blot analysis. It was found that expression at 30 °C with 0.1 mM IPTG induction was the most suitable for trastuzumab. In contrast, the full-length expression of chimeric anti-VEGF required induction with 1 mM IPTG at 30 °C., however, 1 mM IPTG induction resulted in more full-length IgG. In conclusion, the present study indicated that E coli could be successfully used for the full-length expression of IgG by suitably modifying the expression conditions.

1 December 2020 in IOP Conference Series: Earth and Environmental Science
Verified
Conference Paper
Open access
PDF file
AKA Kamthong
A Kamthong
RPRungtiva P. Poo-arporn
Rungtiva P. Poo-arporn
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
Monoclonal antibodies (mAbs) have been used extensively both for treatment and diagnostics. Phage display has been successfully used for isolation of many mAbs currently sold in the market. However, the main drawback is that it could result in a large number of false positives. In this study, we explored the feasibility of combination of two powerful antibody isolation techniques, phage display and Functional Ligand-binding Identification by Tat-based Recognition of Associating Proteins (FLI-TRAP), to identify nanobodies (Nbs) that are specific to HBsAg, an antigen commonly used for hepatitis B infection diagnostics. A synthetic camelized human nanobody library was subjected to 2 rounds of biopanning against HBsAg adr subtype, commonly found in southeast Asia. As expected, sequencing analysis of all 12 randomly selected clones from biopanning showed truncated Nbs, representing false positive. Full-length Nb genes were amplified from the phage eluted during the 2nd round of biopanning was subcloned into FLI-TRAP system for isolation. For evaluation, 16 clones were also randomly picked and submitted for sequencing analysis. Interestingly, 15 out of 16 clones had the same sequence and were full-length Nb, so C1 was used to represent these clones. C10, however, was truncated at framework 3. ELISA result of crude extract showed that C1 showed binding activity ≈ 4.5 fold higher than reference Nb and ≈ 1.46 fold lower than commercial purified monoclonal antibodies while its WB result showed that C1 had a higher protein yield than the reference Nb. C10 did not show ELISA signal nor was detected in WB, thus truncation was confirmed since the detection was performed using anti-FLAG antibody specific to FLAG epitope tag fused to the C-terminus of Nb. Nonetheless, our study demonstrated the feasibility to use FLI-TRAP after initial phage display screening to easily identify full-length Nbs. This combined platform would be powerful tool for easy isolation of Nb against new target as well as for affinity maturation.

7 March 2016 in Entropy
Verified
Journal Article
Open access
PDF file
JTJittrawan Thaiprasit
Jittrawan Thaiprasit
BKBoonserm Kaewkamnerdpong
Boonserm Kaewkamnerdpong
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
SCSupapon Cheevadhanarak
Supapon Cheevadhanarak
AMAsawin Meechai
Asawin Meechai
RNA-RNA interactions play a crucial role in gene regulation in living organisms. They have gained increasing interest in the field of synthetic biology because of their potential applications in medicine and biotechnology. However, few novel regulators based on RNA-RNA interactions with desired structures and functions have been developed due to the challenges of developing design tools. Recently, we proposed a novel tool, called iDoDe, for designing RNA-RNA interacting sequences by first decomposing RNA structures into interacting domains and then designing each domain using a stochastic algorithm. However, iDoDe did not provide an optimal solution because it still lacks a mechanism to optimize the design. In this work, we have further developed the tool by incorporating a genetic algorithm (GA) to find an RNA solution with maximized structural similarity and minimized hybridized RNA energy, and renamed the tool iDoRNA. A set of suitable parameters for the genetic algorithm were determined and found to be a weighting factor of 0.7, a crossover rate of 0.9, a mutation rate of 0.1, and the number of individuals per population set to 8. We demonstrated the performance of iDoRNA in comparison with iDoDe by using six RNA-RNA interaction models. It was found that iDoRNA could efficiently generate all models of interacting RNAs with far more accuracy and required far less computational time than iDoDe. Moreover, we compared the design performance of our tool against existing design tools using forty-four RNA-RNA interaction models. The results showed that the performance of iDoRNA is better than RiboMaker when considering the ensemble defect, the fitness score and computation time usage. However, it appears that iDoRNA is outperformed by NUPACK and RNAiFold 2.0 when considering the ensemble defect. Nevertheless, iDoRNA can still be an useful alternative tool for designing novel RNA-RNA interactions in synthetic biology research. The source code of iDoRNA can be downloaded from the site http://synbio.sbi.kmutt.ac.th.